Abstract
The application claims a single 1,4-disubstituted piperazine derivative, a H3 antagonist, and its use for the treatment of inflammatory diseases, especially allergic rhinitis. Compositions of the agent alone or in combination with a H1 antagonist are claimed. The antagonist is indicated to have low CNS penetration.
Patent Details
Title l-{4-[(l-Cyclobutyl-4-piperidinyl)oxy]- phenyl]-4-{[4-(methylsulfonyl)phenyl]carbonyl piperazin as histamin H3 antagonist.
Assignee Glaxo Group Ltd.
Inventors Hancock AP, Hodgson ST, Vinader BM, Washington ML.
Priority date 24/02/05.
Filing date 22/02/06.
Publication date 31/08/06.
Publication no. WO2006090142.